ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, it was suggested that the ABL1 kinase inhibitor asciminib (ABL001), in combination with nilotinib, could eradicate the development of chronic myelogenous leukaemia in xenografts [215].